Puma Biotechnology (PBYI) EBT Margin (2017 - 2026)
Puma Biotechnology's (PBYI) quarterly EBT Margin came in at 7.65% in Q1 2026, down 1475.0% YoY from 0.56% in Q1 2025, and down 133.73% on a QoQ basis from 22.67% in Q4 2025.
Puma Biotechnology (PBYI) EBT Margin (2017 - 2026) Analysis & Trends
Puma Biotechnology (PBYI) has 10 years of EBT Margin data on file, last reported at 7.65% in Q1 2026.
- Quarterly EBT Margin fell 1475.0% year-over-year to 7.65% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 12.8% (up 943.0% YoY) and the FY2025 annual result came in at 15.67%, changed N/A from the prior year.
- EBT Margin retreated to 7.65% in Q1 2026, from 22.67% in the prior quarter.
- In the past five years, EBT Margin ranged from a high of 25.59% in Q3 2024 to a low of 20.08% in Q4 2024.
- A 5-year average of 4.39% and a median of 4.24% in 2023 frame the typical range for EBT Margin.
- Annual changes were most pronounced in 2022 — EBT Margin soared 9601 bps — and 2024, when it plunged 3782 bps.
- Tracing PBYI's EBT Margin over 5 years: stood at 6.06% in 2022, then surged by 393 bps to 17.74% in 2023, then slumped by 213 bps to 20.08% in 2024, then soared by 213 bps to 22.67% in 2025, then plunged by 134 bps to 7.65% in 2026.
- The last three EBT Margin figures came in at 7.65% (Q1 2026), 22.67% (Q4 2025), and 16.97% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 41.75% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 35.61% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 34.77% |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 18.33% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -94.22% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 12.09% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 13.77% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -2.67% |
| 10 | Puma Biotechnology | 451.24 Mn | 357.33 Mn | 44.03 Mn | 14.59% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 14.59% |
| Mar 31, 2026 | -7.65% |
| Dec 31, 2025 | 22.67% |
| Sep 30, 2025 | 16.97% |
| Jun 30, 2025 | 11.76% |
| Mar 31, 2025 | 7.10% |
| Dec 31, 2024 | -20.08% |
| Sep 30, 2024 | 25.59% |
| Jun 30, 2024 | -8.82% |
| Mar 31, 2024 | -10.50% |
| Dec 31, 2023 | 17.74% |
| Sep 30, 2023 | 10.71% |
| Jun 30, 2023 | 4.24% |
| Mar 31, 2023 | 2.93% |
| Dec 31, 2022 | -6.06% |
| Sep 30, 2022 | -0.51% |
| Jun 30, 2022 | 15.84% |
| Mar 31, 2022 | -7.36% |
| Dec 31, 2021 | 8.01% |
| Sep 30, 2021 | -96.52% |